MG
REGN icon

Michael Gelband’s Regeneron Pharmaceuticals REGN Stock Holding History

Michael Gelband’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,756
Closed -$2.9M – 1972
2026
Q1 		$2.9M Sell
3,756
-66,024
-95% -$50.5M 0.02% 630
2025
Q4 		$53.9M Buy
69,780
+42,048
+152% +$28.6M 0.42% 27
2025
Q3 		$15.6M Buy
+27,732
New +$15.7M 0.16% 117
2025
Q1 		– Sell
-721
Closed -$514K – 1915
2024
Q4 		$514K Sell
721
-7,047
-91% -$5.91M ﹤0.01% 1146
2024
Q3 		$8.17M Buy
7,768
+4,282
+123% +$4.77M 0.05% 275
2024
Q2 		$3.66M Sell
3,486
-9,785
-74% -$9.49M 0.03% 541
2024
Q1 		$12.8M Buy
+13,271
New +$12.6M 0.1% 174
2023
Q3 		– Sell
-2,858
Closed -$2.05M – 2062
2023
Q2 		$2.05M Sell
2,858
-28,975
-91% -$22.3M 0.02% 792
2023
Q1 		$26.2M Buy
31,833
+12,777
+67% +$9.64M 0.22% 73
2022
Q4 		$13.7M Buy
+19,056
New +$14.1M 0.2% 118
2022
Q3 		– Sell
-6,390
Closed -$3.78M – 2233
2022
Q2 		$3.78M Buy
+6,390
New +$4.15M 0.05% 506
2022
Q1 		– Sell
-1,918
Closed -$1.21M – 2596
2021
Q4 		$1.21M Buy
1,918
+786
+69% +$483K 0.01% 968
2021
Q3 		$685K Sell
1,132
-566
-33% -$351K 0.01% 1226
2021
Q2 		$948K Sell
1,698
-15,064
-90% -$7.63M 0.01% 1039
2021
Q1 		$7.93M Buy
16,762
+9,032
+117% +$4.4M 0.12% 169
2020
Q4 		$3.73M Buy
7,730
+4,840
+167% +$2.61M 0.04% 331
2020
Q3 		$1.62M Buy
+2,890
New +$1.75M 0.03% 474
2020
Q2 		– Sell
-2,469
Closed -$1.21M – 1985
2020
Q1 		$1.21M Buy
+2,469
New +$1.02M 0.07% 267
2019
Q1 		– Sell
-4,803
Closed -$1.79M – 752
2018
Q4 		$1.79M Buy
+4,803
New +$1.76M 0.13% 62

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Michael Gelband's REGN Position: Q2 2026 in Review

Michael Gelband sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3,756 shares — an estimated $2.9M sold.

Michael Gelband first reported a position in REGN in Q4 2018 and held it in 19 quarters. The position peaked at $53.9M in Q4 2025. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Michael Gelband reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 3,756 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.9M.
  • Michael Gelband first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 19 quarters.
  • Michael Gelband's Regeneron Pharmaceuticals position peaked at $53.9M in Q4 2025.
  • 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.